Quarterly ResultMay 5, 2026, 07:23 AM
Precision BioSciences Q1 Revenue $10.8M; Net Loss $18.4M
AI Summary
Precision BioSciences reported strong first-quarter 2026 financial results, with total revenues increasing to $10.8 million and net loss decreasing to $18.4 million. The company maintained a robust cash balance of $125.8 million, extending its cash runway through 2028. Significant progress was made across its clinical pipeline, including advancing the PBGENE-HBV and PBGENE-DMD programs, securing regulatory approvals, and receiving a $7.5 million milestone payment from TG Therapeutics.
Key Highlights
- Q1 2026 total revenues were $10.8 million, up from less than $0.1 million in Q1 2025.
- Net loss for Q1 2026 was $18.4 million, or $(0.75) per share, compared to $20.6 million in Q1 2025.
- Cash, cash equivalents, and restricted cash totaled $125.8 million as of March 31, 2026.
- Cash runway is expected to fund operations and data milestones through 2028.
- Advanced PBGENE-HBV Phase 1/2a ELIMINATE-B trial; late-breaking poster accepted at EASL Congress 2026.
- PBGENE-DMD advanced to Phase 1/2 FUNCTION-DMD trial with FDA IND clearance and Fast Track designation.
- Received a $7.5 million clinical milestone payment from TG Therapeutics for Azer-Cel.